Intended for licensed healthcare professionals located in Finland.
PEMAZYRE monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. Contraindications for use include hypersensitivity to the active substance or excipients and concomitant use with St John’s wort.1
Pemigatinib is a kinase inhibitor of FGFR1, 2 and 3. It inhibits FGFR phosphorylation and signalling, and decreases cell viability in cells expressing FGFR genetic alterations, including point mutations, amplifications, and fusions or rearrangements.1
FGFR2 fusion positivity status must be known prior to initiation of PEMAZYRE therapy. Assessment for FGFR2 fusion positivity in tumour specimens should be performed with an appropriate diagnostic test.1
Pemigatinib inhibits FGFR1–3 phosphorylation and signalling1
Figure created by Incyte, based on reference 1.
1. PEMAZYRE® (pemigatinib). Summary of Product Characteristics: Sections 4.1, 4.2, 4.3 and 5.1. June 2022.